Since chronic treatment with dopamine D2 receptor agonists improves insulin-resistance and glucose intolerance20,21,26, it is likely that acute treatment with dopamine D2 receptor agonists increases plasma glucose levels, while chronic treatment with dopamine D2 receptor agonists decreases plasma glucose levels. This evidence concerns the gene DRD2 and Insulin resistance.